Evaluation of the biological potency of new agmatine analogs of growth hormone-releasing hormone in the bovine.
Roberge. S S; Johnson. H E HE; Zarandi. M M; Schally. A V AV; Reeves. J J JJ
Key Findings
- All four agmatine‑modified GHRH analogs produced a dose‑dependent increase in GH in cows.
- JG‑73 and MZ‑2‑75 gave significantly higher GH release than the native hGHRH(1‑29)NH2 at a mid‑range dose (0.25 µg/kg).
- When averaged across all doses, JG‑73, MZ‑2‑75, and MZ‑2‑51 were 11.8‑, 11.3‑, and 6.5‑times more potent than the native peptide.
Practical Outcomes
- These results suggest that adding an agmatine group to GHRH can dramatically boost its ability to trigger growth‑hormone release—at least in cattle. For biohackers, the data hint that similar modified peptides might be more effective GH secretagogues, but human studies are missing, so no concrete dosing or safety guidance can be drawn yet.
Summary
In cows, four new versions of the growth‑hormone‑releasing hormone (GHRH) that have an agmatine group at the end were tested. Two of these versions (JG‑73 and MZ‑2‑75) caused a stronger release of growth hormone than the regular human GHRH peptide, and overall three of the new peptides were up to about 12 times more potent on a weight‑for‑weight basis.
Abstract
Four new growth hormone-releasing hormone (GHRH) analogs with C-terminal agmatine were compared with the parent human GHRH(1-29)NH2 fragment to assess their abilities to increase serum concentrations of growth hormone (GH) in the bovine. The four analogs were: [D-Ala2, Nle27] GHRH(1-28)Agm (JG-73); [desNH2-Tyr1, Ala15, Nle27] GHRH(1-28)Agm (MZ-2-51); [desNH2-Tyr1, Ala15, D-Lys21, Nle27] GHRH(1-28)Agm (MZ-2-75); and [desNH2-Tyr1, D-Lys12,21, Ala15, Nle27] GHRH(1-28)Agm (MZ-2-87). The special characteristic of all four GHRH analogs is that arginine was replaced by agmatine (Agm) in Position 29. Five pregnant Holstein cows received these peptides subcutaneously at the following doses: 0.0156, 0.0625, 0.25, 1, and 4 micrograms/kg body wt. Each cow received each analog-dose combination according to a 5 x 5 Greco-Latin square design repeated for the 5-week treatment. Each cow also received saline vehicle only at the end of the 5-week treatment. Blood samples were collected from 30 min before until 360 min after treatment injection. Total area under the GH response curves for the 6-hr sampling period for each dose of each GHRH analog was compared. There was a linear dose-dependent GH release in response to hGHRH(1-29)NH2 and its four GHRH(1-28)Agm analogs. At the dose of 0.25 micrograms/kg, two GHRH analogs, JG-73 and MZ-2-75, stimulated greater GH release than hGHRH(1-29)NH2 (P less than 0.05). No differences were seen at the two lowest doses, 0.0625 and 0.156 micrograms/kg. When both total area under the GH response curves and GH peak amplitudes for each treatment were averaged for all doses, JG-73 and MZ-2-75 stimulated greater GH release than hGHRH(1-29)NH2 (P less than 0.05). In summary, three GHRH(1-28)Agm analogs, JG-73, MZ-2-75, and MZ-2-51, were found to be 11.8, 11.3, and 6.5 times more potent, respectively, on a weight basis, than hGHRH(1-29)NH2 in stimulating the release of GH in cows.
Study Information
pubmed
1992
1992-05-01T00:00:00.000Z
10.3181/00379727-200-43401
3
24